1. **Title of the module**

LABS613 Finance and Corporate Governance

1. **School or partner institution which will be responsible for management of the module**

Centre for Higher and Degree Apprenticeships

1. **The level of the module (Level 4, Level 5, Level 6 or Level 7)**

Level 6

1. **The number of credits and the ECTS value which the module represents**

15 credits (7.5 ECTs)

1. **Which term(s) the module is to be taught in (or other teaching pattern)**

Flexible delivery model

Autumn and/or Spring and/or Summer

1. **Prerequisite and co-requisite modules**

N/A

1. **The programmes of study to which the module contributes**

BSc (Hons) in Applied Bioscience

1. **The intended subject specific learning outcomes.
On successfully completing the module students will be able to:**

8.1 Understand the key aspects associated with the pharmaceutical industry in terms of its current monetary worth and growth, with a regional breakdown.

8.2 Demonstrate systematic understanding of key aspects of pharmaceutical commercial awareness.

8.3 Apply key aspects of the pharmaceutical company model, including the small biotech model, clinical research organisations (CROs), and an overview of business planning, inwell-defined contexts.

8.4 Critically analyse the basics of business integrity and business ethics.

1. **The intended generic learning outcomes.
On successfully completing the module students will be able to:**

9.1 Develop and demonstrate an ability to work and communicate effectively with others.

9.2 Analyse, evaluate and correctly interpret data.

9.3 Present and communicate data effectively.

9.4 Obtain and use information from a variety of sources as part of self-directed learning.

9.5 Manage their time and use their organisation skills within the context of self-directed learning.

1. **A synopsis of the curriculum**

The module gives an introduction into finance and corporate governance in the pharmaceutical industry. It considers the whole gamete of pharmaceutical industry business models, from small biotech start-ups, to clinical research organisations (CROs), and large Pharma. It considers the pharmaceutical industry in terms of its global and national economic impact, and details regional breakdown before analysing current strategies for pharmaceutical commercial awareness. Finally, it explores business integrity and business ethics associated with the pharmaceutical industry.

1. **Reading list (Indicative list, current at time of publication. Reading lists will be published annually)**

Zimerli, W. C., Ritcher, K., and Holzinger, M. (2007) *Corporate Ethics and Corporate Governance.* Springer.

1. **Learning and teaching methods**

Blended distance learning:

 Contact Hours: 100 hours

 Private Study Time: 50 hours

 Total Learning Time: 150 hours

1. **Assessment methods**
	1. Main assessment methods

Portfolio and essay assignment (essay; 1000 words)

Weighting:

Essay Assignment 50%

Portfolio 50% - composed of 5 individual assignments where topics are applied to the workplace

The pass mark for this module is 40%.

13.2 Reassessment methods

Like for like

1. ***Map of module learning outcomes (sections 8 & 9) to learning and teaching methods (section12) and methods of assessment (section 13)***

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Module learning outcome** | 8.1 | 8.2 | 8.3 | 8.4 | 8.5 | 9.1 | 9.2 | 9.3 | 9.4 | 9.5 |
| **Learning/ teaching method** |  |  |  |  |  |  |  |  |  |  |
| **Private Study** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** |
| Teaching | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** |  |
| Work based experience | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** |
| **Assessment method** |  |  |  |  |  |  |  |  |  |  |
| Essay (1000 words) | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** |
| Portfolio | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** | **x** |

1. **Inclusive module design**

The School/Collaborative Partner recognises and has embedded the expectations of current equality legislation, by ensuring that the module is as accessible as possible by design. Additional alternative arrangements for students with Inclusive Learning Plans (ILPs)/declared disabilities will be made on an individual basis, in consultation with the relevant policies and support services.

The inclusive practices in the guidance (see Annex B Appendix A) have been considered in order to support all students in the following areas:

a) Accessible resources and curriculum

b) Learning, teaching and assessment methods

1. **Campus(es) or centre(s) where module will be delivered**

Blended distance learning – delivered from Medway or Canterbury campus

1. **Internationalisation**

Finance and corporate governance, in the pharmaceutical sector, is important internationally. Global investors are demanding higher standards of corporate governance which is pressurising companies to adapt current practices. With regards to the intended learning outcomes, in particular 8.1, 8.2, and 8.4, the target learning outcomes within this module are applicable worldwide as part of the universal principles of finance and corporate governance that is associated with the pharmaceutical industry. With regard to subject content, the material within the syllabus is applied to a wide range of international contexts, where it draws on and compares current standards and regulations across Europe. Furthermore, it has been developed with global employers to have an international focus.

**FACULTIES SUPPORT OFFICE USE ONLY**

**Revision record – all revisions must be recorded in the grid and full details of the change retained in the appropriate committee records.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Date approved | Major/minor revision | Start date of delivery of revised version | Section revised | Impacts PLOs (Q6&7 cover sheet) |
| 05/10/20 | Minor | Sep 20 | 13 | No |
|  |  |  |  |  |